Adjuvant therapy and long-term management of differentiated thyroid carcinoma

Seminars in Surgical Oncology

Volumn 16, Issue 1, 1999, Pages 30-33

  Sherman, Steven I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Combined modality therapy; Follicular adenocarcinoma; Levothyroxine; Papillary carcinoma; Radiotherapy dosage; Thyroid neoplasms

Indexed keywords

INDIUM; LEVOTHYROXINE; OCTREOTIDE; ORGANOPHOSPHORUS COMPOUND; RADIOACTIVE IODINE; RADIOISOTOPE; TECHNETIUM COMPLEX; THALLIUM; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

ADJUVANT THERAPY; CANCER RISK; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; IMMUNORADIOMETRIC ASSAY; NEEDLE BIOPSY; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; THYROID CARCINOMA; THYROID GLAND;

ANTITHYROID AGENTS; CARCINOMA; HUMANS; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS;

EID: 0031725549     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199901/02)16:1<30::AID-SSU6>3.0.CO;2-H     Document Type: Article

References (44)

1. Singer PA, Cooper DS, Daniels GH, et al: Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996; 156:2165-2172.
2. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [published erratum in Am J Med 1995;98:2151] [comment in: Am J Med 1994;97:499-500]. Am J Med 1994;97:418-428.
3. Wong JB, Kaplan MM, Meyer KB, Pauker SG: Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 1990;19:741-760.
4. DeGroot LJ, Kaplan EL, McCormick M, Straus FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:41424.
5. Beienvaltes WH, Rabbani R, Dmuchowski C, et al: An analysis of "ablation of thyroid remnants" with 1-131 in 511 patients from 19471984: experience at University of Michigan. J Nucl Med 1984 ;25:1287-1293.
6. Maxon HR, Thomas SR, Hertzberg VS, et al: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-941.
7. rd, Englaro EE, Thomas SR, et al: Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients [comment in: J Nucl Med 1993;34:524-526]. J Nucl Med 1992;33:1132-1136.
8. McCowen KD, Adler RA, Ghaed N, et al: Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 1976;61:52-58.
9. DeGroot LJ, Reilly M: Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med I982;96:51-53.
10. Johansen K, Woodhouse NJ, Odugbesan O: Comparison of 1073 MBq and'3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer [comment in: J Nucl Med 1991;32:1640-1641]. J Nucl Med 1991 ;32:252-254.
11. Logue JP, Tsang R\V, Brierley JD, Simpson \VJ: Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 1994;67:1127-1131.
12. Sherman SI, Tielens ET, Sostre S, et al: Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-634.
13. Crile G Jr: The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth. Cancer 1957;10:1119-1137.
14. Mazzaferri EL, Young RL: Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-518.
15. Simpson WJ, Panzarella T, Carruthers JS, et al: Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiât Oncol Biol Phys 1988;14:1063-1075.
16. Pujol P, Daures JP, Nsakala N, et al: Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-4323.
17. Ross DS, Neer RM, Ridgway EC, Daniels GH: Subclinical hyperthryoidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine.AmJMed 1987;82:1167-1170.
18. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B: Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine [comment in: Ann Intern Med 1991;114:339-340]. Ann Intern Med 1990;113:265-269.
19. Diamond T, Nery L, Hales I: A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1990;72:11841188.
20. Sawin CT, Geller A, Wolf PA, et al: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons [comment in: N Engl J Med 1994;331:1302-1303]. N Engl J Med 1994;331:1249-1252.
21. Fazio S, Biondi B, Carella C, et al: Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of -blockade. J Clin Endocrinol Metab 1995;80:2222-2226.
22. Biondi B, Fazio S, Carella C, et al: Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine [comment in J Clin Endocrinol Metab 1993;77:332-333]. J Clin Endocrinol Metab 1993;77:334-338.
23. Biondi B, Fazio S, Carella C, et al: Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine [comment in: J Clin Endocrinol Metab 1994;78:1026-1027]. J Clin Endocrinol Metab I994;78:1028-1033.
24. Shapiro LE, Sievert R, Ong L, et al: Minimal cardiac effects in asymptomatic athreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997;82:2592-2595.
25. Sherman SI, Chiu AC, Kopelen H, Zoghbi W: Minimal resting car-diac effects of TSH-suppressive doses of L-thyroxine [Abstract]. Thyroid 1997;7:S58.
26. Cooper DS, Specker B, Ho M, et al: TSH suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. In press.
27. Shaha AR, Loree TR, Shah JP: Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118:1131-1138.
28. Spencer ÇA, Wang CC: Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls [Review]. Endocrinol Metab Clin North Am 1995:24:841-863.
29. Ozata M, Suzuki S, Miyamoto T, et al: Serum thyroglobulin in the follow-up of patients treated with differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
30. Lo Gerfo P, ColacchioTA, Colacchio DA, Feind CR: Effect of TSH stimulation on serum thyroglobulin in metastatic thyroid cancer. J SurgOncol 1980; 14:195-200.
31. Pacini F, Lari R, Mazzeo S, et al: Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol 1985;23:40511.
32. Müller-Gärtner HW, Schneider C: Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988;61:976-981.
33. Meier ÇA, Braverman LE, Ebner SA, et al: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188-196.
34. Ladenson P\V, Braverman LE, Mazzaferri EL, et al: Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma [comment in: N Engl J Med 1997;337:928-930]. N Engl J Med 1997;337:888-896.
35. Black EG, Sheppard MC, Hoffenberg R: Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol 1987;27:115-120.
36. Mariotti S, Barbesino G, Caturegli P, et al: Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol Metab 1995:80:468-472.
37. Spencer ÇA, Takeuchi M, Kazarosyan M, et al: Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1 Hill 27.
38. ColeTG, Johnson D, Eveland BJ, Nahm MH: Cost-effective method for detection of "hook effect" in tumor marker immunometric assays [letter]. Clin Chem 1993:39:695-696.
39. Antonelli A, Miccoli P, Fedeghini M, et al: Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995:5:25-28.
40. Franceschi M, Kusic Z, Franceschi D, et al: Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37:446-451.
41. Baudin E, Schlumberger M, Lumbroso J, et al: Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996;81:2541-2544.
42. Lind P, Gallowitsch HJ, Langsteger W, et al: Technetium-99mtetrofosmin whole body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997;38:348-352.
43. Burman KD, Anderson JH, Wartofsky L, et al: Management of patients with thyroid carcinoma: application of thallium-201 scintigraphy and magnetic resonance imaging [comment in: J Nucl Med 1991:32:1463-1464]. J Nucl Med 1990;31:1958-1964.
44. Gagel RF, Goepfert H, Callender DL: Changing concepts in the pathogenesis and management of thyroid carcinoma [Review]. CA Cancer J Clin 1996;46:261-283.